The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Official Title: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Study ID: NCT02810743
Brief Summary: Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Institut Paoli Calmettes, Marseille, , France
Hopital Tenon, University Marie-Curie, Paris, , France
Medical spectrum Twente, Enschede, Overijssel, Netherlands
Antoni van Leeuwenhoek, Amsterdam, , Netherlands
AZVU, Amsterdam, , Netherlands
University Medical Center Groningen, Groningen, , Netherlands
LUMC, Leiden, , Netherlands
Maastricht University Medical Center, Maastricht, , Netherlands
Radboud UMC, NIjmegen, , Netherlands
Erasmus Medical Center Cancer Institute, Rotterdam, , Netherlands
University Medical Center Utrecht, Utrecht, , Netherlands
Name: Sabine Linn, Prof. MD
Affiliation: NKI-AvL
Role: PRINCIPAL_INVESTIGATOR